Why 70% of Indian HealthTech Trials Never Convert Into Revenue — And the Evidence Translation Stack Fixing It

70% of Indian HealthTech Trials Never Convert to Revenue — Here’s Why

India is one of the most powerful clinical validation engines in the world.

World-class hospitals. Massive patient volumes. Highly trained clinicians.
Yet despite this, most Indian healthtech startups stall right after “successful pilots.”

According to multiple investor interviews and procurement analyses, over 70% of clinical trials in Indian healthtech never convert into long-term commercial contracts.

Not because the tech doesn’t work.
Not because the outcomes aren’t real.

But because evidence isn’t packaged in a way buyers can act on.

This is the Clinical Evidence Translation Gap — and it is one of the biggest silent killers of Indian healthtech scale and fundraising momentum.

The Real Problem: Clinical Proof ≠ Buyer Proof

Indian founders are taught to believe:

“If the data is strong, buyers will come.”

In reality, buyers don’t buy evidence.
They buy risk reduction, budget alignment, and internal justification.

Hospitals, payers, employers, and pharma partners each ask a different question:

• Will this reduce cost or increase throughput?

• Which budget line pays for this?

• How does this survive procurement review?

• Can I defend this decision internally?

Most clinical trials in India answer none of these.

That’s why India needs not just trials — but a translation system.

The India Clinical Evidence Translation Stack

This ecosystem has six distinct layers.
Most startups activate one or two.
Almost none orchestrate all six.

That’s the failure point.

1️⃣ Clinical Sites

What they provide: legitimacy and scale
What they don’t provide: commercial framing

India’s hospitals generate outstanding clinical data — but their job ends at clinical validation, not commercial enablement.

Without downstream translation, trials remain:

• PDFs

• Journal publications

• Internal reports

None of which close deals.

Founder mistake: assuming hospital brand = buyer trust.

Role: Generate credible, large-scale clinical data trusted by buyers

Active Indian Institutions

1. All India Institute of Medical Sciences (Delhi & network)

2. Christian Medical College Vellore

3. Apollo Hospitals

4. Fortis Healthcare

5. Manipal Hospitals

6. Narayana Health

7. Medanta

8. Aster DM Healthcare

9. KIMS-Ushalakshmi Centre

10. Sir Ganga Ram Hospital

11. PGIMER Chandigarh

12. Tata Memorial Centre

13. LV Prasad Eye Institute

14. Aravind Eye Care

15. Sri Ramachandra Medical Centre

16. Jaslok Hospital

17. Hinduja Hospital

18. Amrita Institute of Medical Sciences

2️⃣ Trial Platforms

What they provide: operational execution
What they don’t provide: buyer relevance

CROs and trial platforms optimize for:

• Protocol adherence

• Data integrity

• Regulatory submission

They are not incentivized to:

• Align endpoints to procurement logic

• Translate outcomes into economic impact

• Customize results for different buyer types

Founder mistake: outsourcing thinking, not just execution.

Role: Run, manage, and digitize trials beyond academic publication

Active Organizations

1. CliniOps

2. Clinion

3. Clinevo

4. MediSage

5. TrialX

6. Medidata India

7. Veeva India

8. IQVIA India

9. Lambda Therapeutic Research

10. Syngene Clinical

11. GVK BIO

12. Veeda Clinical Research

13. Accutest

14. Siro Clinpharm

15. Cliantha Research

16. Axis Clinicals

17. Reliance Life Sciences

18. PAREXEL India

3️⃣ Evidence Analytics

What they provide: insights
What they don’t provide: decisions

Analytics vendors can surface:

• Accuracy improvements

• Sensitivity/specificity

• Outcome deltas

But buyers don’t purchase insights — they purchase outcomes with consequences.

Unless analytics are explicitly mapped to:

• Cost avoidance

• Productivity gains

• Revenue protection

They remain “interesting,” not actionable.

Role: Convert raw clinical results into interpretable, decision-grade evidence

Active Companies

1. Tata Consultancy Services Life Sciences

2. Fractal Analytics

3. Mu Sigma

4. SigTuple

5. HealthPlix Analytics

6. Qure.ai

7. Innovaccer

8. Strand Life Sciences

9. Indegene

10. Cartesian Consulting

11. LatentView Analytics

12. Axtria India

13. Tiger Analytics

14. Course5 Intelligence

15. Celebal Technologies

16. Gramener

17. AIndra Systems

18. Predible Health

4️⃣ Procurement Rails

What they provide: the final gate
What they don’t provide: forgiveness

Procurement doesn’t care how good your trial was.

They care about:

• Documentation

• Compliance

• Budget alignment

• Risk ownership

If your evidence isn’t already translated into procurement language before you enter this stage, the deal is already lost.

Role: Turn “interest” into signed contracts

Active Institutions

1. Government e-Marketplace

2. Central Government Health Scheme

3. National Health Authority

4. Ayushman Bharat Digital Mission

5. HLL Infra Tech Services

6. HSCC India

7. ESIC

8. State Health Agencies

9. Apollo Procurement

10. Fortis Supply Chain

11. Manipal Supply Chain

12. Tata Trusts Health Programs

13. Infosys BPM Healthcare

14. Wipro Health Platforms

15. TCS Healthcare Platforms

16. Reliance Health Ventures

17. Aditya Birla Health

18. Star Health Insurance

The Missing System: Evidence → Revenue Orchestration

Here’s the uncomfortable truth:

India doesn’t have an evidence problem.
It has a systems problem.

Startups run trials.
Consultants write reports.
Sales teams chase buyers.

But no one owns the full translation loop:

Clinical → Economic → Buyer → Procurement → Contract

That’s why even strong startups stall between:

• Pilot and purchase

• Validation and valuation

• Proof and fundraising

The Framework That Actually Works

High-performing companies treat evidence as a commercial asset, not a scientific artifact.

They run a repeatable system:

1️⃣ Design trials with buyers in mind
2️⃣ Translate endpoints into economic KPIs
3️⃣ Package proof per buyer type
4️⃣ Pre-empt procurement objections
5️⃣ Use evidence to accelerate fundraising

This is not a tooling problem.
It’s an operating discipline.

Where Most Founders Need Help

Founders don’t fail because they lack intelligence or data.
They fail because they try to solve a systems problem piecemeal.

What’s usually missing:

• Cross-layer orchestration

• Buyer-specific translation

• Evidence-led sales systems

• Procurement-ready narratives

That’s where external, system-level intervention matters.

Final Thought

India is one of the best places in the world to generate clinical proof.

But until startups learn how to translate that proof into revenue,
the ecosystem will continue to produce:

• Brilliant trials

• Underfunded companies

• Missed scale opportunities

The winners in 2026 won’t be the ones with more data —
they’ll be the ones with better translation systems.